CN111603440A - Gynecological gel foaming agent and preparation method thereof - Google Patents
Gynecological gel foaming agent and preparation method thereof Download PDFInfo
- Publication number
- CN111603440A CN111603440A CN202010597997.9A CN202010597997A CN111603440A CN 111603440 A CN111603440 A CN 111603440A CN 202010597997 A CN202010597997 A CN 202010597997A CN 111603440 A CN111603440 A CN 111603440A
- Authority
- CN
- China
- Prior art keywords
- chitosan
- mixed solution
- parts
- water
- gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000004088 foaming agent Substances 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 229920001661 Chitosan Polymers 0.000 claims abstract description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000003380 propellant Substances 0.000 claims abstract description 14
- 239000004094 surface-active agent Substances 0.000 claims abstract description 13
- 239000000022 bacteriostatic agent Substances 0.000 claims abstract description 10
- 230000005451 protein repair Effects 0.000 claims abstract description 10
- 239000002904 solvent Substances 0.000 claims abstract description 10
- 229920003169 water-soluble polymer Polymers 0.000 claims abstract description 10
- 239000011259 mixed solution Substances 0.000 claims description 53
- 238000003756 stirring Methods 0.000 claims description 25
- 239000000243 solution Substances 0.000 claims description 24
- -1 polyoxyethylene Polymers 0.000 claims description 14
- 239000006260 foam Substances 0.000 claims description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 9
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 8
- 210000000130 stem cell Anatomy 0.000 claims description 8
- 238000003825 pressing Methods 0.000 claims description 5
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 claims description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 4
- 229920002413 Polyhexanide Polymers 0.000 claims description 4
- 229920000289 Polyquaternium Polymers 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 4
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 4
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 4
- 229960002216 methylparaben Drugs 0.000 claims description 4
- 229960000502 poloxamer Drugs 0.000 claims description 4
- 229920001983 poloxamer Polymers 0.000 claims description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 4
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims description 4
- 235000010199 sorbic acid Nutrition 0.000 claims description 4
- 239000004334 sorbic acid Substances 0.000 claims description 4
- 229940075582 sorbic acid Drugs 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 claims description 3
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 claims description 2
- 239000005714 Chitosan hydrochloride Substances 0.000 claims description 2
- 229920002907 Guar gum Polymers 0.000 claims description 2
- 108010039918 Polylysine Proteins 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 235000010298 natamycin Nutrition 0.000 claims description 2
- 239000004311 natamycin Substances 0.000 claims description 2
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 claims description 2
- 229960003255 natamycin Drugs 0.000 claims description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 2
- 229920000656 polylysine Polymers 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 2
- 229960003415 propylparaben Drugs 0.000 claims description 2
- 229940075554 sorbate Drugs 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 238000000034 method Methods 0.000 claims 2
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 10
- 206010046914 Vaginal infection Diseases 0.000 abstract description 4
- 201000008100 Vaginitis Diseases 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 208000027418 Wounds and injury Diseases 0.000 abstract description 3
- 208000025865 Ulcer Diseases 0.000 abstract description 2
- 210000003679 cervix uteri Anatomy 0.000 abstract description 2
- 230000035876 healing Effects 0.000 abstract description 2
- 231100000397 ulcer Toxicity 0.000 abstract description 2
- 239000003814 drug Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 238000005189 flocculation Methods 0.000 description 2
- 230000016615 flocculation Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- 229940043375 1,5-pentanediol Drugs 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000007031 hydroxymethylation reaction Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Dispersion Chemistry (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gynecology & Obstetrics (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a gynecological gel foaming agent, which comprises a gel solution and a propellant, wherein the gel solution comprises chitosan or chitosan derivatives, a solubilizer, a water-soluble polymer, a surfactant, a bacteriostatic agent, a protein repair factor and water. The invention has the beneficial effects that: the foaming agent has the advantages of simple preparation method, stable product performance, good antibacterial and bactericidal effects, and safe, sanitary and convenient use, and is suitable for treating various vaginitis, protecting cervix, repairing wound surface, and promoting ulcer healing.
Description
Technical Field
The invention relates to the field of gynecological cleaning agents, in particular to a gynecological gel foaming agent and a preparation method thereof.
Background
Gynecological diseases such as vaginitis are common frequently-occurring diseases, and common diseases such as pruritus, burning pain, irritation, abnormal fluid and the like have great influence on normal work and life. Many clinical medicines can produce some side effects, and influence the health to a certain extent. In addition to vaginitis, cervical cancer is also a gynecological disease that is prone to occur, causing a great deal of damage to the female body and health.
Disclosure of Invention
The invention overcomes the defects in the prior art and provides a gynecological gel foaming agent and a preparation method thereof.
The purpose of the invention is realized by the following technical scheme.
A gynecological gel foaming agent comprises a gel solution and a propellant, wherein the gel solution comprises chitosan or chitosan derivatives, a solubilizer, a water-soluble polymer, a surfactant, a bacteriostatic agent, a protein repair factor and water.
Preferably, the gel solution comprises the following components in parts by weight: 0.1-3 parts of chitosan or chitosan derivative, 0.5-5 parts of solubilizer, 0.1-5 parts of water-soluble polymer, 0.1-10 parts of surfactant, 0.01-5 parts of bacteriostatic agent, 0.001-1 part of protein repair factor and the balance of water.
In any of the above schemes, preferably, the propellant is added in a proportion of 1-50 parts per hundred parts of the gel solution.
In any of the above schemes, preferably, the chitosan or chitosan derivative is one or more of chitosan, chitosan oligosaccharide, chitosan quaternary ammonium salt, chitosan hydrochloride, chitosan lactate, and carboxymethyl chitosan.
In any of the above embodiments, preferably, the solubilizer is one or more of glycerol, propylene glycol, butylene glycol, pentylene glycol, hydrogenated castor oil.
In any of the above embodiments, preferably, the water-soluble polymer is one or more of hydroxyethyl cellulose, hydroxypropyl methylcellulose, carboxymethyl cellulose, polyquaternium 1, polyquaternium 6, guar gum, and xanthan gum.
In any of the above schemes, preferably, the surfactant is one or more of alkylphenol ethoxylates, polyoxyethylene fatty acid esters, polyoxyethylene alkylamides, sucrose fatty acid esters, span, tween and poloxamer.
In any of the above schemes, preferably, the bacteriostatic agent is one or more of sorbic acid or sorbate, methyl paraben, ethyl paraben, propyl paraben, benzyl alcohol, polyhexamethylene biguanide, polylysine and natamycin.
In any one of the above embodiments, preferably, the protein repair factor is an adipose-derived stem cell extract.
A preparation method of a gynecological gel foaming agent comprises the following steps:
firstly, adding a solubilizer in a formula amount into water in a formula amount, and uniformly stirring to obtain a mixed solution I;
secondly, adding chitosan or chitosan derivatives with the formula amount into the mixed solution I, and uniformly stirring to obtain a mixed solution II;
thirdly, adding the water-soluble polymer with the formula amount into the mixed solution II, and uniformly stirring to obtain a mixed solution III;
fourthly, adding the surfactant with the formula amount into the third mixed solution, and uniformly stirring to obtain a fourth mixed solution;
fifthly, adding the bacteriostatic agent and the protein repair factor in the formula amount into the mixed solution IV, and uniformly stirring to obtain a mixed solution V;
and sixthly, filling the mixed solution V into a bottle, and then pressing the propellant with the formula amount into the bottle to obtain the gynecological gel foaming agent.
The invention has the beneficial effects that:
the foaming agent has the same osmotic pressure as body fluid, can effectively permeate into vagina, is uniformly distributed in the vaginal cavity and on the surface of skin, has fine and dense foam and good biocompatibility with the skin, improves the absorption rate of the medicine, increases the bioavailability of the medicine, and promotes the absorption of the medicine preparation.
The chitosan or chitosan derivative is commonly used as a carrier material in the field of medicine, can control the release of medicines, has good antibacterial performance and can effectively inhibit the propagation of bacteria and fungi.
The foaming agent has the advantages of simple preparation method, stable product performance, good antibacterial and bactericidal effects, and safe, sanitary and convenient use, and is suitable for treating various vaginitis, protecting cervix, repairing wound surface, and promoting ulcer healing.
Detailed Description
The technical solution of the present invention is further illustrated by the following specific examples.
Chitosan or chitosan derivative is subjected to chemical reaction to prepare N, O-hydroxymethylation chitosan with bacteriostatic activity, wherein the relative molecular mass has obvious influence on the bacteriostatic activity, for example, the bacteriostatic activity is obviously enhanced along with the reduction of the relative molecular mass, and when the relative molecular mass is lower than 5000, the material has obvious effect of inhibiting and killing staphylococcus aureus; after the chitosan is dissolved in acid, the-NH 2 on the sugar chain is combined with H < + > to form a strong positive charge cationic group, which is very beneficial to improving the acidic constitution;
solubilizers have been widely used for solubilizing poorly soluble drugs to obtain clear or clear solutions of higher concentration suitable for therapeutic needs;
the water-soluble polymer has flocculation effect, is an effective polymeric flocculant, and has charged parts capable of neutralizing the charges of colloidal particles, destroying the stability of the colloidal particles in water, promoting the collision of the colloidal particles, and entangling a plurality of fine particles together through macromolecular long-chain bridges to aggregate the fine particles into large particles, thereby accelerating the sedimentation. The flocculation and sedimentation speed is high, the sludge dewatering efficiency is high, and the special effect is achieved on the treatment of certain wastewater;
the surface active agent can be used as a bactericide and a disinfectant in the pharmaceutical industry, the sterilization and disinfection effects of the surface active agent are attributed to the fact that the surface active agent and the bacterial biofilm protein are denatured or nonfunctional due to strong interaction, the disinfectants have relatively high solubility in water, and can be used for skin disinfection, wound or mucosa disinfection, instrument disinfection and environment disinfection before operation according to the using concentration; meanwhile, the surfactant has the effect of changing a solution system, increasing the viscosity and thickening or increasing the foam of the system;
the bacteriostatic agent has obvious antibacterial effect, strong deodorization effect, and is colorless, transparent and odorless;
the protein repair factor has self-renewal, proliferation and multi-directional differentiation potential, can be differentiated into fat cells, cartilage cells, muscle cells, osteoblasts, nerve cells, glial cells and islet cells, can secrete various angiogenesis promoting factors and anti-apoptosis factors to resist inflammation and oxidation, and can resist damage of oxygen free radicals
The propellant helps to hasten the formation of foam;
the gynecological external antibacterial foaming agent has the characteristics of broad-spectrum physical antibacterial property, no drug resistance, lasting efficacy, stronger sterilizing power when meeting water, safety, environmental protection and the like, is an ideal novel gynecological antibacterial anti-inflammatory preparation, adopts the foaming agent to generate fine and soft foam, can be quickly dispersed through filling and retaining effects, ensures that the main drug is distributed and permeated in the medicine application part in a solution state, has direct effect, is beneficial to absorption, is more thorough in sterilization, and achieves more effective treatment.
Example 1
A gel solution of the gynecological gel foaming agent is prepared from the following raw materials in percentage by weight: 0.5 part of chitosan, 2 parts of glycerol, 0.5 part of hydroxyethyl cellulose, 0.2 part of alkylphenol polyoxyethylene, 0.1 part of methyl paraben, 0.01 part of adipose-derived stem cell extracting solution and 96.6 parts of water; 10 parts of propellant are added into the gel solution.
A preparation method of a gynecological gel foaming agent comprises the following steps:
step one, adding 0.5 part of glycerol into 96.6 parts of water, and uniformly stirring to obtain a mixed solution I;
secondly, adding 0.5 part of chitosan into the mixed solution I, and uniformly stirring to obtain a mixed solution II;
thirdly, adding 0.5 part of hydroxyethyl cellulose into the mixed solution II, and uniformly stirring to obtain a mixed solution III;
fourthly, adding 0.2 part of alkylphenol polyoxyethylene into the third mixed solution, and uniformly stirring to obtain a fourth mixed solution;
fifthly, adding 0.1 part of methyl paraben and 0.01 part of adipose-derived stem cell extracting solution into the fourth mixed solution, and uniformly stirring to obtain a fifth mixed solution;
and sixthly, filling the mixed solution five into a bottle, and then pressing 10 parts of propellant into the mixed solution five to obtain the gynecological gel foaming agent.
Example 2:
a gel solution of the gynecological gel foaming agent is prepared from the following raw materials in percentage by weight: 1 part of chitosan lactate, 3 parts of propylene glycol, 0.5 part of hydroxypropyl cellulose, 0.3 part of polyoxyethylene alkyl amide, 0.2 part of sorbic acid, 0.01 part of an adipose-derived stem cell extracting solution and 94.9 parts of water; 20 parts of propellant are added into the hundred parts of gel solution.
A preparation method of a gynecological gel foaming agent comprises the following steps:
step one, adding 3 parts of propylene glycol into 94.9 parts of water, and uniformly stirring to obtain a mixed solution I;
secondly, adding 1 part of chitosan lactate into the first mixed solution, and uniformly stirring to obtain a second mixed solution;
step three, adding 0.5 part of hydroxypropyl cellulose into the mixed solution II, and uniformly stirring to obtain a mixed solution III;
fourthly, adding 0.3 part of polyoxyethylene alkylamide into the third mixed solution, and uniformly stirring to obtain a fourth mixed solution;
fifthly, adding 0.2 part of sorbic acid and 0.01 part of adipose-derived stem cell extracting solution into the fourth mixed solution, and uniformly stirring to obtain a fifth mixed solution;
and sixthly, filling the mixed solution five into a bottle, and then pressing 20 parts of propellant into every hundred parts of the mixed solution five to obtain the gynecological gel foaming agent.
Example 3:
the gynecological gel foaming agent is prepared from the following raw materials in percentage by weight: 2 parts of chitosan quaternary ammonium salt, 4 parts of pentanediol, 1 part of carboxymethyl cellulose, 0.5 part of poloxamer, 0.02 part of polyhexamethylene biguanide, 0.01 part of adipose-derived stem cell extracting solution and 92.38 parts of water; 30 parts of propellant is added into the hundred parts of gel solution.
A preparation method of a gynecological gel foaming agent comprises the following steps:
step one, adding 4 parts of pentanediol into 92.38 parts of water, and uniformly stirring to obtain a mixed solution I;
secondly, adding 2 parts of chitosan quaternary ammonium salt into the mixed solution I, and uniformly stirring to obtain a mixed solution II;
step three, adding 1 part of cellulose glycolate into the mixed solution II, and uniformly stirring to obtain a mixed solution III;
fourthly, adding 0.5 part of poloxamer into the third mixed solution, and uniformly stirring to obtain a fourth mixed solution;
fifthly, adding 0.02 part of polyhexamethylene biguanide and 0.01 part of adipose-derived stem cell extracting solution into the mixed solution IV, and uniformly stirring to obtain a mixed solution V;
and sixthly, filling the mixed solution five into a bottle, and then pressing 30 parts of propellant into every hundred parts of the mixed solution five to obtain the gynecological gel foaming agent.
The three embodiments of the present invention have been described in detail, but the description is only for the preferred embodiments of the present invention and should not be construed as limiting the scope of the present invention. All equivalent changes and modifications made within the scope of the present invention shall fall within the scope of the present invention.
Claims (10)
1. The gynecological gel foaming agent is characterized in that: the gel comprises a gel solution and a propellant, wherein the gel solution comprises chitosan or chitosan derivatives, a solubilizer, a water-soluble polymer, a surfactant, a bacteriostatic agent, a protein repair factor and water.
2. The gynecological gel foam formulation of claim 1, characterized in that: the gel solution comprises the following components in parts by weight: 0.1-3 parts of chitosan or chitosan derivative, 0.5-5 parts of solubilizer, 0.1-5 parts of water-soluble polymer, 0.1-10 parts of surfactant, 0.01-5 parts of bacteriostatic agent, 0.001-1 part of protein repair factor and the balance of water.
3. The gynecological gel foam formulation according to claim 2, characterized in that: the propellant is added in a proportion of 1-50 parts per hundred parts of the gel solution.
4. The gynecological gel foam formulation according to claim 3, characterized in that: the chitosan or chitosan derivative is one or more of chitosan, chitosan oligosaccharide, chitosan quaternary ammonium salt, chitosan hydrochloride, chitosan lactate and carboxymethyl chitosan.
5. The gynecological gel foam formulation according to claim 3, characterized in that: the solubilizer is one or more of glycerol, propylene glycol, butanediol, pentanediol and hydrogenated castor oil.
6. The gynecological gel foam formulation according to claim 3, characterized in that: the water-soluble polymer is one or more of hydroxyethyl cellulose, hydroxypropyl methyl cellulose, carboxymethyl cellulose, polyquaternium 1, polyquaternium 6, guar gum and xanthan gum.
7. The gynecological gel foam formulation according to claim 3, characterized in that: the surfactant is one or more of alkylphenol polyoxyethylene, polyoxyethylene fatty acid ester, polyoxyethylene alkylamide, sucrose fatty acid ester, span, tween and poloxamer.
8. The gynecological gel foam formulation according to claim 3, characterized in that: the bacteriostatic agent is one or more of sorbic acid or sorbate, methyl paraben, ethyl paraben, propyl paraben, benzyl alcohol, polyhexamethylene biguanide, polylysine and natamycin.
9. The gynecological gel foam formulation according to claim 3, characterized in that: the protein repair factor is an adipose-derived stem cell extracting solution.
10. A process for the preparation of a gynaecological gel foam according to any of claims 1 to 9, characterized in that: the method comprises the following steps:
firstly, adding a solubilizer in a formula amount into water in a formula amount, and uniformly stirring to obtain a mixed solution I;
secondly, adding chitosan or chitosan derivatives with the formula amount into the mixed solution I, and uniformly stirring to obtain a mixed solution II;
thirdly, adding the water-soluble polymer with the formula amount into the mixed solution II, and uniformly stirring to obtain a mixed solution III;
fourthly, adding the surfactant with the formula amount into the third mixed solution, and uniformly stirring to obtain a fourth mixed solution;
fifthly, adding the bacteriostatic agent and the protein repair factor in the formula amount into the mixed solution IV, and uniformly stirring to obtain a mixed solution V;
and sixthly, filling the mixed solution V into a bottle, and then pressing the propellant with the formula amount into the bottle to obtain the gynecological gel foaming agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010597997.9A CN111603440A (en) | 2020-06-28 | 2020-06-28 | Gynecological gel foaming agent and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010597997.9A CN111603440A (en) | 2020-06-28 | 2020-06-28 | Gynecological gel foaming agent and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111603440A true CN111603440A (en) | 2020-09-01 |
Family
ID=72196950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010597997.9A Pending CN111603440A (en) | 2020-06-28 | 2020-06-28 | Gynecological gel foaming agent and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111603440A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113576978A (en) * | 2021-08-27 | 2021-11-02 | 黄桦 | Composition containing orange medicinal material extract and preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102872159A (en) * | 2012-09-29 | 2013-01-16 | 广东同德药业有限公司 | Nano-silver chitosan gel foam preparation for treating vaginal bacterial inflammation, and preparation method thereof |
-
2020
- 2020-06-28 CN CN202010597997.9A patent/CN111603440A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102872159A (en) * | 2012-09-29 | 2013-01-16 | 广东同德药业有限公司 | Nano-silver chitosan gel foam preparation for treating vaginal bacterial inflammation, and preparation method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113576978A (en) * | 2021-08-27 | 2021-11-02 | 黄桦 | Composition containing orange medicinal material extract and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108135745B (en) | Efficient novel fast deposition film-forming compositions for wound treatment | |
| KR101155884B1 (en) | Chemically modified polyaminosaccharide by a hydrocarbyl sultone compound | |
| CN101977589B (en) | Chitosan gel for dermatological use, production method therefor and use of same | |
| CN105079858B (en) | Liquid dressing and its preparation method are repaired in a kind of wound sterilization | |
| EP2937101A1 (en) | Semi-fluidic composition for lubricating, moisture retaining, disinfecting, sterilizing and method using the same | |
| CN102091097B (en) | Washing-free puerpera perineum medical-care gel and preparation method thereof | |
| JP2007505124A (en) | Antibacterial compositions and methods | |
| CN113491709B (en) | Multifunctional high-efficiency compound disinfectant and preparation method thereof | |
| WO2013060936A1 (en) | Aqueous antimicrobial composition containing coniferous resin acids | |
| US11259521B2 (en) | Topical antiseptic system | |
| CN108158995A (en) | A kind of gynaecology's anti-bacteria foaming agent containing chitosan and preparation method thereof | |
| CN107668062B (en) | Olanexidine aqueous solution based on hyaluronic acid and preparation method and application thereof | |
| CN111603440A (en) | Gynecological gel foaming agent and preparation method thereof | |
| CN103860821A (en) | Broad-spectrum disinfectant composition | |
| AU2008274042B2 (en) | Chitosan carboxyalkylamide hydrogel, preparation thereof and cosmetic and dermatological use thereof | |
| TWI400038B (en) | Aqueous solution of olanexidine, method of preparing the aqueous solution, and disinfectant | |
| CN107646862B (en) | Olanexidine aqueous solution based on ascorbic acid and preparation method and application thereof | |
| US20230284627A1 (en) | Antimicrobial compositions and methods of use and for making same | |
| CN111297802A (en) | Anti-inflammatory and antibacterial composition | |
| CN113082029B (en) | Wound cleaning disinfectant | |
| RU2810573C2 (en) | Bioactive hydrogel based on high molecular weight chitosan and method of its extemporaneous production | |
| CN118215488A (en) | Phosphate and arginine containing compositions and delivery of such compositions for virulence inhibition | |
| KR20230112488A (en) | A method for preparing a triple composite wound dressing containing povidone iodine and trimethyl chitosan with secured formulation stability | |
| CN117100729A (en) | Private part antibacterial composition, private part nursing product, and preparation methods and applications thereof | |
| RU2448719C2 (en) | Dermatological agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200901 |
|
| RJ01 | Rejection of invention patent application after publication |